Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke

Journal of Stroke and Cerebrovascular Diseases

Volumn 22, Issue 2, 2013, Pages 100-106

  Georgiadis, Alexandros L ^a   Cordina, Steve M ^a   Vazquez, Gabriela ^a   Tariq, Nauman ^a   Suri, M Fareed K ^a   Lakshminarayan, Kamakshi ^a   Adams, Harold P ^b   Qureshi, Adnan I ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Aspirin resistance; aspirin treatment failure; ischemic stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; DANAPAROID;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK; SMOKING;

EID: 84872373289     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2011.06.017     Document Type: Article

References (35)

1. D.L. Bhatt, and E.J. Topol Scientific and therapeutic advances in antiplatelet therapy Nat Rev Drug Discov 2 2003 15 28
2. Antiplatelet Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
3. A. Algra, and J. van Gijn Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia J Neurol Neurosurg Psychiatry 60 1996 197 199
4. A. Algra, and J. van Gijn Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin J Neurol Neurosurg Psychiatry 66 1999 255
5. C. Patrono, B. Coller, and G.A. FitzGerald Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 3 Suppl 2004 234S 264S
6. G.J. Hankey, and J.W. Eikelboom Aspirin resistance Lancet 367 2006 606 617
7. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators JAMA 279 1998 1265 1272
8. Tissue plasminogen activator for acute ischemic stroke The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group N Engl J Med 333 1995 1581 1587
9. T.G. Kwiatkowski, R.B. Libman, and M. Frankel Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group N Engl J Med 340 1999 1781 1787
10. S.C. Patel, S.R. Levine, and B.C. Tilley Lack of clinical significance of early ischemic changes on computed tomography in acute stroke JAMA 286 2001 2830 2838
11. H.P. Adams Jr., B.H. Bendixen, and L.J. Kappelle Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment Stroke 24 1993 35 41
12. P.A. Gum, K. Kottke-Marchant, and P.A. Welsh A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 2003 961 965
13. M.R. Mueller, A. Salat, and P. Stangl Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty Thromb Haemost 78 1997 1003 1007
14. K.H. Grotemeyer Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients Thromb Res 63 1991 587 593
15. K.H. Grotemeyer, H.W. Scharafinski, and I.W. Husstedt Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients Thromb Res 71 1993 397 403
16. J.D. Snoep, M.M. Hovens, and J.C. Eikenboom Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis Arch Intern Med 167 2007 1593 1599
17. P. Hjemdahl Aspirin resistance testing not ready for «prime time» Heart 95 2009 1220 1222
18. M.R. Buchanan, L. Schwartz, and M. Bourassa Results of the BRAT study - A pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery Can J Cardiol 16 2000 1385 1390
19. U.S. Tantry, K.P. Bliden, and P.A. Gurbel Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation J Am Coll Cardiol 46 2005 1705 1709
20. M. Lordkipanidze, C. Pharand, and E. Schampaert A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 28 2007 1702 1708
21. U.S. Tantry, E. Mahla, and P.A. Gurbel Aspirin resistance Prog Cardiovasc Dis 52 2009 141 152
22. C.M. Helgason, K.L. Tortorice, and S.R. Winkler Aspirin response and failure in cerebral infarction Stroke 24 1993 345 350
23. G. Cotter, E. Shemesh, and M. Zehavi Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin? Am Heart J 147 2004 293 300
24. J.M. Sweeny, D.A. Gorog, and V. Fuster Antiplatelet drug 'resistance'. Part 1: Mechanisms and clinical measurements Nat Rev Cardiol 6 2009 273 282
25. C.M. Helgason, K.M. Bolin, and J.A. Hoff Development of aspirin resistance in persons with previous ischemic stroke Stroke 25 1994 2331 2336
26. F.M. Pulcinelli, P. Pignatelli, and A. Celestini Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients J Am Coll Cardiol 43 2004 979 984
27. M.I. Chimowitz, M.J. Lynn, and H. Howlett-Smith Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis N Engl J Med 352 2005 1305 1316
28. J.P. Mohr, J.L. Thompson, and R.M. Lazar A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke N Engl J Med 345 2001 1444 1451
29. W.K. Hass, J.D. Easton, and H.P. Adams Jr. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group N Engl J Med 321 1989 501 507
30. J.C. Grotta, J.W. Norris, and B. Kamm Prevention of stroke with ticlopidine: Who benefits most? TASS Baseline and Angiographic Data Subgroup Neurology 42 1992 111 115
31. Mohr JP. Evidence of aspirin and warfarin failure in the WARRS study. Presented at the 27th International Stroke Conference, San Antonio, TX, February 7-9, 2002.
32. T.N. Turan, L. Maidan, and G. Cotsonis Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis Stroke 40 2009 505 509
33. J.K. Lovett, A.J. Coull, and P.M. Rothwell Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies Neurology 62 2004 569 573
34. P.M. Rothwell, M. Eliasziw, and S.A. Gutnikov Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery Lancet 363 2004 915 924
35. V.N. Thijs, and G.W. Albers Symptomatic intracranial atherosclerosis: Outcome of patients who fail antithrombotic therapy Neurology 55 2000 490 497